Piperazine derivative having affinity for the histamine H3 receptor
US8288389B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 4, 2008 |
| Grant date | Oct 16, 2012 |
| Priority date | — |
| Expiry date | Feb 7, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to 1-(1-methylethyl)-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]carbonyl}piperazineor a pharmaceutically acceptable salt thereof, in particular the hydrochloride salt thereof and crystalline forms of the hydrochloride salt; to processes for the preparation of the compound or its salt; to compositions containing it; and to its use in the treatment or prophylaxis of neurological or psychiatric diseases, such as cognitive impairment, fatigue or a sleep disorder, for example in a mammal such as a human.The compound or a salt thereof has affinity for and is an antagonist and/or inverse agonist of the histamine H3 receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.